Replies to post #188579 on Biotech Values

[goodJohnhunting]

More seriously, it would significantly surprise me if it DIDN'T have some effect on the immune system. It is an antibody and it is chimeric. And that is what makes it a great gravy train - because most disease modalities are complex enough that if you just look at enough different components of enough different models you'll find something positive. Checkpoint? Yep. ...

Well, you've just described nearly all immunotherapy cell based compounds.. Either antibody or cytokine, their targeting cell surface molecules, and some checkpoint/pathway etc.. They can all say that, and many do..

Targeting PS, and its immuno association, then calling it a checkpoint pathway, is no different than BMY categorizing anti-PD1 as a checkpoint inhibitor, IMO..

If I were Peregrine, I would have just stuck with "Anti-PS targeting" and left it at that. I get your point and have said the same over on the PPHM board. However, my point being, there is no correct answer..

All the best,
John

[GD]

I have a question:

Who is behind the switch? Who doe not want the PII trial
to success? If the science is questionable, there is no
need to take the risk to tempt the PII, IMO.